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The prevalence of obesity and its associated comorbidities has grown to epidemic proportions in the US and worldwide. Thus,
developing safe and eﬀective therapeutic approaches against these widespread and debilitating diseases is important and timely.
Activation of peroxisome proliferator-activated receptors (PPARs) α, γ,a n dδ through several classes of pharmaceuticals can
prevent or treat a variety of metabolic and inﬂammatory diseases, including type II diabetes (T2D). Thus, PPARs represent
important molecular targets for developing novel and better treatments for a wide range of debilitating and widespread obesity-
related diseases and disorders. However, available PPAR γ agonistic drugs such as Avandia have signiﬁcant adverse side eﬀects,
including weight gain, ﬂuid retention, hepatotoxicity, and congestive heart failure. An alternative to synthetic agonists of PPAR
γ is the discovery and development of naturally occurring and safer nutraceuticals that may be dual or pan PPAR agonists. The
purpose of this paper is to summarize the health eﬀects of three plant-derived PPAR agonists: abscisic acid (ABA), punicic acid
(PUA), and catalpic acid (CAA) in the prevention and treatment of chronic inﬂammatory and metabolic diseases and disorders.
1.Introduction
During the past two decades, the prevalence of obesity
has risen to epidemic proportions in the United States,
and current estimates indicate that approximately 67% of
the population is overweight and one-third is obese. This
burgeoning problem has brought with it numerous health
and ﬁscal concerns. Obesity is associated with a number of
chronic diseases such as type II diabetes (T2D), cardiovas-
cular disease (CVD), chronic kidney disease (CKD), nonal-
coholic fatty liver disease (NAFLD), obstructive sleep apnea
(OSA), gallbladder diseases, and various types of cancers [1],
and obesity-related spending is currently estimated at $147
billion per year [2]. This number has been anticipated to rise
to $344 billion, or 21% of all health care spending, in 2018 if
rates continue on their current trajectory [3].
PPARs are the receptors for endogenous lipid molecules
(i.e., prostaglandins or hydroxy-containing PUFA such as
12/15-hydroxyeicosatetraenoic (HETE), 13-hydroxyoctade-
cadienoic (HODE)) molecular targets for drugs against
type 2 diabetes [4–6] and represent promising new targets
for the treatment and prevention of inﬂammatory disorders
such as IBD [7, 8]. PPARs belong to the superfamily of
nuclear hormone receptors with 48 members identiﬁed in
the human genome. There are three known PPAR isoforms;
α, β or δ,a n dγ,w h i c hd i ﬀer in their tissue distribution
and functional activity [9]. Functionally, PPARs regulate
inﬂammation, immunity, and metabolism [10]. PPAR acti-
vation and expression is controlled by a diverse set of natural
and synthetic molecules, including nutrients, nonnutrient
endogenous ligands, and drugs (i.e., thiazolidinediones
(TZDs) and ﬁbrates).
Activation of the nuclear receptor peroxisome prolif-
erator-activated receptor γ (PPAR γ) has shown eﬃcacy in
the treatment of type II diabetes [11], inﬂammatory bowel
disease [12, 13], colorectal cancer [14, 15], and inﬂuenza
virus-induced pulmonary inﬂammation [16]. Thiazolidine-
diones (TZDs) are highly eﬃcacious in activating PPAR γ,
but the key representative of this class of drugs, rosiglitazone
(Avandia), is associated with signiﬁcant adverse side eﬀects,2 Journal of Obesity
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Figure 1: Chemical structures of the isoprenoid abscisic acid (a) and the conjugated linolenic acid stereo- or regioisomers punicic acid- (9Z,
11E,1 3 E-) octadeca-9, 11, 13-trienoic acid (b) and catalpic acid- (9E,1 1 E,1 3 Z-) octadeca-9, 11, 13-trienoic acid (c).
including weight gain, congestive heart failure, and ﬂuid
retention [6]. Although the results of the recent action
to control cardiovascular disease in diabetes (ACCORD)
trial did not report side eﬀects associated with the use of
the ﬁbrate class of PPAR α agonists [17], other studies
have reported that they can increase the risk for myopa-
thy, cholelithiasis, and venous thrombosis [18]. Therefore,
based on the concerns regarding cardiovascular safety of
rosiglitazone, in 2010, the European Medicines Agency took
rosiglitazone oﬀ the market in Europe. Moreover, the Food
and Drug Administration restricted the use of rosiglitazone
in the United States to situations in which other medications
are not eﬀective, thereby minimizing its use. Thus, there is
an urgent need to develop novel and safer agonists of PPAR
α and γ as therapeutics for obesity, diabetes, inﬂammation,
and cancer. Our group has already developed a pipeline of
naturally occurring compounds that activate PPARs [12, 19–
26]a n da r eb o t he ﬃcacious and safe, thereby conﬁrming
that in spite of the side eﬀects of some synthetic agonists,
PPARs remain valid drug/nutraceutical discovery targets.
We have also set up the systems for virtually screening
large compound libraries [27]. This paper describes the
mechanisms of action of abscisic acid (ABA), punicic acid
(PUA), and catalpic acid (CAA) (Figure 1) and their eﬀects
in mouse models of obesity, diabetes, and atherosclerosis.
2.AbscisicAcid
In 2009, the story of the isoprenoid phytohormone abscisic
acid (ABA) and its elusive receptors were selected as runner
up for “breakthrough of the year” by Science magazine [28].
This distinction awarded to ABA-research is attributable
in part to the importance that ABA holds as a signaling
compound. In plants, ABA is involved in numerous develop-
mental and adaptive stress responses, including those related
to stomatal opening and closing, pathogen defense, embryo
and seed development, germination, promotion of seed
desiccation tolerance and dormancy, and general growth and
reproduction [29]. Researchers over the past 30 years have
identiﬁed over 100 loci and numerous second messengers
involved in ABA-induced responses, messengers such as
calcium, reactive oxygen species (ROS), cyclic nucleotides,
and phospholipids [29].
During the past few years, our laboratory and others
have been investigating the potential of ABA as a bioactive
compound for the prevention and treatment of diseases. In
2007, Bruzzone et al. found that ABA can be produced by
human granulocytes and proposed that it may function as
an endogenous signaling compound in mammals [30]. The
signaling pathway identiﬁed by Bruzzone et al. is remarkably
similar to that described in plants. The components of
the pathway include a pertussis-toxin-sensitive G-protein-
coupled receptor on the plasma membrane, cAMP over-
production, protein kinase A- (PKA-) induced activation
of ADP-ribosyl cyclase CD38, cADP-ribose generation, and
an increase in intracellular calcium [30]. The lanthionine
synthetase C-like protein 2 (LANCL2), a protein which
shares high-sequence homology to the ABA-binding protein
GCR2, was recently recognized as being critical for ABA-
induced responses in the mammalian cells [31].
Research in our laboratory has focused on in vivo
eﬀects of ABA administration. We initially determined
that ABA increases the activity of the nuclear receptor
peroxisome proliferator-activated receptor γ (PPAR γ)i n
3T3-L1 preadipocytes [22]. Because it has been shown to be
aninﬂuentialproteininanumberofcellsandtissuesintegral
to glucose homeostasis, uncovering how PPAR γ activation
improves the insulin response has been a complex task. In
white adipose tissue (WAT), a region which expresses high
levels of PPAR γ, TZDs increase the diﬀerentiation of new
adipocytes, thereby preventing adipocyte hypertrophy and
lipid eﬄux into peripheral tissues [32]. PPAR γ activation
also inhibits macrophage and lymphocyte-induced inﬂam-
mation [33], a hallmark of obesity and its comorbidities, and
its presence has been shown to be important in the proper
function of key metabolic regions such as skeletal muscle
[34], the liver [35], and pancreas [36].
Despite the beneﬁts associated with PPAR γ activation,
TZDs are associated with unwanted side eﬀects, such as
weight gain, ﬂuid retention, and congestive heart fail-
ure, which diminish their appeal as therapeutic agents
[6]. Recently, the TZD rosiglitazone was associated with
increased risk of myocardial infarction and cardiovascu-
lar mortality although another TZD, pioglitazone (Actos),
appears to be safer [37]. An objective in our research with
ABA was to determine whether it could replicate some of theJournal of Obesity 3
beneﬁcial eﬀects associated with PPAR γ activation without
causing adverse side eﬀects.
3.ABA inTypeII Diabetes
Our laboratory’s ﬁrst study with ABA was designed to assess
its eﬃcacy in a mouse model of obesity and diabetes [22].
Db/db mice were fed high-fat diets containing a racemic
ABA mixture at 0, 100, 200, 400, and 800mg/kg diet. After
a 5-week ABA supplementation, we observed signiﬁcant
improvements in fasting blood glucose at all doses [22].
There were no side eﬀects noted with any of the ABA
concentrations. Further testing with ABA continued with
the lowest-eﬀective dose measured (100mg/kg). At this
concentration, ABA supplementation signiﬁcantly improved
glucose tolerance, inhibited WAT macrophage inﬁltration,
and reduced tumor necrosis factor α (TNF-α)m R N A .
Expressions of PPAR γ and PPAR γ-responsive genes CD36
and aP2 were also signiﬁcantly elevated in WAT of ABA-
fed mice in comparison to control-fed mice, indicating that
ABA mimicked TZDs in their capacity to activate PPAR γ
gene regulatory mechanisms in the WAT. Also in line with
increased PPAR γ activity, the number of small adipocytes in
WAT was increased, and interscapular brown adipose tissue
fatpadsweregreaterinABA-fedmice.ABA-fedmicealsohad
signiﬁcantly small liver weights [22], an eﬀect that may be
due to increased expression of hepatic adiponectin receptors.
We next sought to further dissect the cells and tissues
aﬀected by ABA by assessing its eﬀect on the two main
fractions of WAT, adipocytes and stromal vascular cells
(SVCs). The SVC fraction of the WAT, composed of immune
cells, preadipocytes, and endothelial cells and ﬁbroblasts, is
a mainly non-energy storing portion of WAT that plays an
important role in the tissue’s homeostasis. Gene expression
analyses revealed that oral ABA supplementation exerted a
signiﬁcantly more substantial aﬀect on the SVCs. Levels of
PPAR γ and its responsive gene CD36 were more greatly
enhanced in the SVCs than in adipocytes, and SVCs from
ABA-fed mice showed a marked reduction (∼15-fold) in
monocyte chemoattractant protein 1 (MCP-1) mRNA and
protein levels [21]. In line with decreased MCP-1, the
inﬁltrationofCCR2+CD11b+F4/80hi macrophagesintoWAT
was signiﬁcantly decreased by ABA [21]. Chemokine recep-
tor 2 (CCR2) is the receptor for MCP-1, and both proteins
have been associated with obesity-related inﬂammation and
insulin resistance [38, 39].
To determine whether ABA’s aﬀects were dependent on
PPAR γ, control and ABA-supplemented diets were fed to
tissue-speciﬁc PPAR γ knockout mice. The transgenic mice
used in this study, PPAR γ ﬂﬂ; MMTV Cre+ mice, lacked
PPAR γ in all hematopoietic and epithelial cells [12]. After
28 weeks of high-fat feeding, we found that ABA’s ability to
normalize glucose tolerance and reduce WAT inﬂammation
was signiﬁcantly impaired in the MMTV Cre+ mice [21].
T h e r ew e r ea l s on oa d v e r s es i d ee ﬀects observed with this
long-term feeding trial.
Our results show that ABA’s antidiabetic eﬀect is medi-
ated through a PPAR γ-dependent mechanism though
in vitro studies in human and rat pancreatic islet cells
demonstrate that ABA-induced increases in insulin secre-
tion are mediated through cAMP/PKA [40]. Interestingly,
recent ﬁndings in our lab link PPAR γ activation with the
cAMP/PKA signaling pathway. More speciﬁcally, by using
obese db/db mice, we showed that ABA and the TZD
rosiglitazone acted synergistically, rather than competitively,
to reduce WAT macrophage inﬁltration [20]. Further, ABA’s
in vitro activation of PPAR γ in 3T3-L1 preadipocytes
was inhibited by the cAMP-inhibitor 2 5  dideoxyadenosine
or the PKA inhibitor 14–22 myristolated PKA-inhibitor
fragment [20]. There have been previous reports indicating
that PKA activation increases PPAR γ activity [41], and
together these ﬁndings indicate that both cAMP and PPAR
γ may be linked to ABA’s antidiabetic eﬀects.
4.ABAandCardiovascularDisease
In addition to T2D and obesity-related inﬂammation, our
laboratory has also investigated whether dietary ABA may
reduce cardiovascular disease (CVD) risk. When fed to
ApoE-deﬁcient mice as part of a high-fat diet for 12
weeks, ABA treatment signiﬁcantly improved atherosclerosis
lesions and atherosclerosis-related hypertension, reduced
F4/80+CD11b+ macrophage inﬁltration and CD4+ lympho-
cyte inﬁltration into the aortic root, decreased aortic root
inﬂammatory lesions, and decreased aortic expression of
VCAM-1 and MCP-1 [23]. ABA also increased aortic eNOS
expression, both in vivo and in vitro in human aortic
endothelial cells (HAECs) [23]. Short-term (10 minute)
stimulation with ABA in HAECs also increased intracellular
cAMP and NO release [23], an eﬀect that is likely indepen-
dent of binding to and activation of PPAR γ.
Despite our consistent anti-inﬂammatory in vivo ﬁnd-
ings, the eﬀect of ABA on inﬂammation is somewhat
ambiguous. In vitro studies from Bruzzone et al. [30],
Magnone et al. [44], and Bordrato et al. [45]s u g g e s t
that ABA has proinﬂammatory eﬀects as well. In their
work which principally dealt with ABA’s potential eﬀect
on atherogenesis, Magnone et al. show that treatment of
monocytes with ABA activates NF-κB and increases MCP-1
and MMP-9 release [44]. ABA also increased aortic smooth
muscle cell proliferation and migration and was found at
10-fold higher concentrations in human arterial plaques
compared to normal arterial tissue [44]. An alternative
explanation is that ABA levels are greater in atherosclerotic
plaques as a part of an endogenous regulatory mechanism
designed to minimize inﬂammatory lesion development
during atherosclerosis. This alternative explanation would
be consistent with our in vivo ﬁndings in ApoE mice [23],
a well established model of atherosclerosis. Ultimately, the
discrepancy between both reports as to whether ABA treat-
ment is anti- or proinﬂammatory highlights an incomplete
understanding of the mechanisms of immune modulation
by ABA and suggests possible opposing eﬀects depending on
cellular and environmental conditions.
Our most recent studies with ABA in a model of colitis
suggest that its anti-inﬂammatory eﬀects may depend on4 Journal of Obesity
Table 1: Summary of activities of novel classes of peroxisome proliferator-activated receptor (PPAR) agonists.
Punicic acid Catalpic acid Abscisic acid
PPAR α reporter activity1 Yes Yes No
PPAR γ reporter activity1 Yes No Yes
PPAR δ reporter activity1 No Unknown No
PPAR γ ligand-binding activity2 Yes Yes No
PPAR γ in silico Docking3 Yes Yes No
Changes in PPAR-responsive
genes in vivo4
PPAR α in adipose tissue
PPAR γ in skeletal muscle PPAR α in adipose tissue PPAR γ in adipose tissue
Eﬃcacy in tissue-speciﬁc
PPAR γ null mice Impaired Unknown Impaired
PPAR-independent
Mechanisms
Modulation of eicosanoid
synthesis
Decreases cyclooxygenase-2
expression
Lantionine synthetase
component C-like 2, cAMP,
and protein kinase A
Proposed utilities
Gut Anti-inﬂammatory
Blood sugar control
Immune modulator
Antiobesity
Lipid-lowering
Anticancer
Systemic
anti-inﬂammatory
Blood sugar control
Antiatherosclerotic
Immune modulator
1PPAR α, γ,a n dδ reporter activity assays were conducted as previously described [22].
2 PPAR γ ligand-binding assay was performed using a commercially available competitive tracer displacement kit as previously described [42].
3 Molecular modeling and docking studies were performed as previously described [27, 43].
4 PPAR-responsive gene expression was measured in vivo as previously described [12].
T cells, and such ﬁndings may also hold relevance in its
attenuation of CVD risk in ApoE-deﬁcient mice. In the DSS
model of inﬂammatory bowel disease (IBD), we have found
that 5 weeks of ABA supplementation signiﬁcantly improves
colitis severity and decreases cellular adhesion molecule and
proinﬂammatory cytokine expression in the colon [46].
T h ev a l u e sw eo b s e r v e di nt h i sm o d e lw e r em u c hm o r e
substantial than those found in the aortas of ApoE-deﬁcient
mice. Moreover, these beneﬁcial eﬀects of ABA in this model
were impaired in T-cell-speciﬁc PPAR γ knockout mice.
This outcome occurred despite fully functional PPAR γ in
macrophagesandepithelialcells;themaincelltypesinvolved
in the immunopathogenesis of IBD and in the DSS model
of colitis. CD4+CD25+FoxP3+ regulatory T cells appeared
to be important in ABA’s anti-inﬂammatory mechanism in
these IBD studies, as well as the protein CTLA-4, which
was enhanced on CD4+ T cells by ABA in vitro through a
PPAR γ-dependent mechanism [46]. These recent ﬁndings
in our colitis model corroborate earlier results indicating
the importance of immune cells in ABA’s anti-inﬂammatory
mechanism and link T cell PPAR γ with ABA’s systemic anti-
inﬂammatory eﬀects.
5.ConjugatedLinolenicAcid Isomers in
Obesity-RelatedComplications
Conjugated linolenic acids (CLnAs) or conjugated triene
fatty acids are found as triglycerides in the seed oils of some
plants belonging to the Punicaceae, Bignoniaceae, Rosaceae,
Curcubitaceae, and Euphorbiaceae families [47]. Glycerides
from these plant sources provide an easily accessible source
of these unusual types of fatty acids, including but not
limited to punicic (PUA), jacaric acid (JAA) catalpic (CAA),
and eleostearic acids (ESA); all of which have demonstrated
some promising health eﬀects by acting as dual or pan-
agonists of PPARs [12, 25, 26]. Of note, PUA is a conjugated
octadecatrienoic acid containing c9, t11, and c13 double
bonds that resembles the cis-9, trans-11 conjugated linoleic
acid (CLA) isomer, a predominant CLA isomer in nature,
ranging from 0.34 to 1.07% of the total fat in dairy products
[48, 49]. Interestingly, CLA has shown eﬃcacy both as an
immune modulatory nutraceutical [49]a sw e l la sap o s s i b l e
antiobesity therapeutic [50]. Although CLA is beyond the
scope of the present paper (see [50]f o rat h o r o u g hr e v i e w ) ,
some of the health eﬀects of CLnAs resemble those of CLA.
6.PUA inTypeIIDiabetesand
Obesity-RelatedInﬂammation
PUA also known as trichosanic acid is a conjugated triene
fatty acid naturally found at high concentrations in the seed
ofPunicagranatum(Punicaceae,Pomegranate)[51]andTri-
chosanthes kirilowii [47]. PUA constitutes 64–83 percent of
the pomegranate seed oil (PSO) [52, 53], but it also contains
minor amounts of ESA, CAA, and JAA [51]. Phytosterols
(i.e.,beta-sitosterol,campesterol,andstigmasterol)werealso
found in quite high concentrations in the PSO (4,089–
6,205mg/kg), about 3-4-fold higher than in soybean oil
[53]. We recently demonstrated a dose-dependent increase
in the ability of PUA to activate PPAR α and γ reporter
activity in 3T3-L1 cells and to bind to PPAR γ and δ ligand-
binding domain [25]. In line with these in vitro ﬁndings, we
alsodemonstrated that oralPUAadministration ameliorated
fasting plasma glucose concentrations and as well as theJournal of Obesity 5
glucose normalizing ability during a glucose tolerance test
in db/db mice, suggesting that PUA prevents or ameliorates
type2diabetes.Theseimprovementsindiseasemarkerswere
accompanied with upregulation of PPAR α-responsive genes
in skeletal muscle and both PPAR α-a n dγ-responsive genes
in intra-abdominal white adipose tissue [25]. Like CLA, PUA
also suppressed the expression of inﬂammatory cytokines
such as TNF-α and NF-κB activation. Furthermore, the
deletion of the PPAR γ gene from immune cells abrogated
the beneﬁcial eﬀect of PUA on glucose normalization and
impaired PUA’s anti-inﬂammatory eﬀect, thereby suggesting
that PUA ameliorates metabolic and inﬂammatory changes
associatedwithobesity,inpart,throughaPPARγ-dependent
mechanism. We have also demonstrated that PUA is safe
in acute toxicity studies in rats [54]. We also demonstrated
that PUA treatment increased the expression of PPAR δ in
pancreatictissue(unpublishedobservationfromourgroup),
suggesting that this isoform may be a potentially interesting
mediator of some of the insulin-sensitizing eﬀects of PUA.
BasedonthephenotypeobservedduringPUAtreatment,the
response of skeletal muscle could also be PPAR δ mediated,
although no evidence of such eﬀect is available at the
moment.
7.CAAinObesityandTypeIIDiabetes
Catalpic acid (CAA) is a conjugated triene fatty acid (trans-
9, trans-11, cis-13 CLnA) naturally found at high concen-
trations in the seed of plants in the Catalpa Scop. Genus,
belongingtotheBignoniaceaefamily.CAA-producingplants
comprise 11 species of trees and shrubs native to East Africa
and America, including Catalpa ovata, Catalpa speciosa,
Catalpa bungei, and Catalpa bignonioides (southern catalpa)
of the family Bignoniaceae. CAA constitutes approximately
60% of the oil of the catalpa seed oil. Even though the
putative medicinal properties of catalpa trees have been
alleged for centuries as a part of popular folklore, little
is known about the eﬀects of CAA on chronic conditions
aﬄicting today’s developed societies such as obesity and type
2 diabetes. For instance, the biological activities of extracts
from Catalpa bignonioides have been investigated in recent
years [55].
We found that oral CAA administration decreased
abdominal fat accumulation, improved glucose homeostasis,
increased plasma HDL cholesterol concentrations, increased
plasma HDL cholesterol concentrations, and decreases
plasma TG levels in mice fed high-saturated fat diets [26].
The lipid-lowering actions of CAA are consistent with
the PPAR α agonistic actions of ﬁbrates [56]. Of note,
ﬁbrates increase HDL cholesterol through a PPAR α-induced
transcriptional activation of liver X receptor, a nuclear
receptor that increases reverse cholesterol transport through
promotion of the ATP-binding cassette transporters ABCA-1
andABCG-1 [57–59]. Additionally, realtime RT-PCRresults
demonstrated that PPAR α and PPAR α-responsive genes
are upregulated in WAT of mice administered CAA, whereas
PPAR γ and δ expression were not signiﬁcantly aﬀected by
CAA in WAT. These data suggest that the metabolic eﬀects
of CAA on glucose and lipid metabolism may be mediated
through a PPAR α-dependent mechanism. In contrast to
ABA and PUA that modulate obesity comorbidities (i.e.,
insulin resistance, diabetes, or systemic inﬂammation), CAA
has a direct eﬀect in reducing adipose tissue accumulation.
8. Concluding Remarks andFutureDirections
While diet and exercise remain the recommended
approaches to prevent and treat obesity and its
comorbidities, nutraceuticals and drugs may play a role
as adjunct therapeutic interventions for controlling certain
aspects of the disease etiopathogenesis. Mounting evidence
demonstrates that naturally occurring compounds such
as ABA, PUA, and CAA can act on well-established
pharmacologic targets such as PPARs and exert their
antidiabetic, anti-inﬂammatory, or antiobesity properties in
animal models. In contrast to synthetic agonists of PPARs,
these plant-derived compounds are safer and may act
through multiple molecular targets. Intervention studies in
humans are necessary to determine whether the beneﬁcial
eﬀects reported in mice translate into clinical improvements
in obese, diabetic, or insulin-resistant individuals.
With regard to the further developments of these com-
pounds, based on the results reported here, CAA will be
furtherdeveloped forantiobesity and lipid-lowering applica-
tions,PUAwillbedevelopedforregulatingbloodsugarlevels
as well as controlling intestinal inﬂammation, and ABA will
be developed for improving insulin sensitivity as a potential
safer alternative to TZD and a systemic anti-inﬂammatory
compound. Additionally, wewillinvestigate the possibility of
synergistic interactions between these compounds and drugs
or other natural products to maximize their eﬃcacy.
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